1,000 Clinical Research Studies Completed
Highlights Vimta's Leadership Among Indian CRO's Serving the Generic Drug Industry
Vimta Labs announced today that it has completed its 1,000th clinical trial. This milestone reflects India’s growing importance in the pharmaceutical development industry, and Vimta’s growing dominance among India’s clinical research organizations (CRO). Considering Vimta’s track record of 25 years in operation, its no wonder that no other Indian CRO has done as many clinical studies.
Vimta Labs is the Indian clinical research organization currently favored by many US generic drug manufacturers to perform high-quality and cost-effective bio-equivalence studies. These studies are performed to test whether a “generic” drug is equivalent to the reference or “branded” version. In recent years, India has become the location-of-choice for many pharmaceutical and biotech companies looking for easy access to patients and low-cost clinical research. Vimta is well positioned to help US generic drug companies conduct large-scale bio-equivilence studies in their 200 bed facility.
“With a highly experienced team of 640 employees, Vimta Labs provides a broad range of drug development services - including clinical trials, analytical, central lab and preclinical services - to pharma and biotech companies globally” said Nageswara Rao, VP-Business Development of Vimta Labs.Vimta can conduct trials in a much shorter timeframe than US based CROs, and for about 50% of the price. Vimta has been audited multiple times by the US FDA for compliance to GCP and GLP.
“Driven by the growing need for trials in patients, Vimta Labs has recently partnered with a number of super specialty hospitals in India to offer clinical end-point studies as well as Phase-II and III trials” says Mr. Rao.
“Vimta Labs is clearly the leader in this field” said Jim Worrell, CEO of Pharma Services Network of Charlotte. “They are providing critical services to many of the top generic drug manufacturers in the USA and around the world. We congratulate Vimta on reaching 1,000 completed studies.” Pharma Services Network represents Vimta Labs in North American market.
Pharma Services Network is a business development company working on behalf of international research organizations, helping them build strong business relationships with US pharmaceutical and biotech companies.
Contacts:
Pharma Services Network
Meghan Stewart, 803-746-4095;
mstewart@pharmaservicesnet.com
